TA-MUC1 as detected by the fully humanized, therapeutic antibody Gatipotzumab predicts poor prognosis in cervical cancer
- 30 July 2018
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 144 (10) , 1899-1907
Abstract
Background Gatipotuzumab is a fully humanized antibody which was designed to detect a cancer-specific glyco-modification of MUC1 (termed ‘TA-MUC1’) and which was optimized to effectively trigger antibody-dependent-cell-mediated cytotoxicity (ADCC) in cancer cells. Clinical trials investigating therapeutic efficacy of this antibody have been published recently. The current analysis aimed to determine whether TA-MUC1—as detected by Gatipotuzumab—is expressed in cervical cancer tissue and whether binding of Gatipotuzumab is associated with clinico-pathological variables including recurrence free (RFS) and overall survival (OS). Methods Cervical cancer tissue (n = 250) was stained for TA-MUC1 using Gatipotuzumab employing a standardized immunohistochemistry protocol. Staining was scored by applying the IR-score. Results were binarized and tested for association to clinico-pathological parameters. Results TA-MUC1 as stained by Gatipotuzumab was detected in 188 (75.2%) out of the 250 cervical cancer cases investigated. Expression of TA-MUC1 was restricted to cancer cells and was positively correlated with viral oncoprotein E6. Membrane staining of TA-MUC1 predicted significantly reduced RFS and OS. Importantly, expression of TA-MUC1 at the cell surface identified a group of early stage cervical cancer patients with exceptional short RFS and OS. Conclusions We report TA-MUC1—the antigen detected by Gatipotzumab—to be widely expressed in cervical cancer tissue and to localize to the cell membrane. The latter is seen as a pre-requisite to target this epitope by antibody-drug conjugates or antibodies eliciting ADCC. Since especially, membrane localization of TA-MUC1 predicted poor prognosis, evaluating Gatipotuzumab for its therapeutic efficacy in cervical cancer may turn attractive.Keywords
This publication has 36 references indexed in Scilit:
- Multicentric and multifocal versusunifocal breast cancer: differences in the expression of E-cadherin suggest differences in tumor biologyBMC Cancer, 2013
- Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patient survivalBMC Cancer, 2012
- Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapyBritish Journal of Cancer, 2012
- Human chorionic gonadotropin and its relation to grade, stage and patient survival in ovarian cancerBMC Cancer, 2012
- TA-MUC1 epitope in non-small cell lung cancerLung Cancer, 2009
- Human papillomavirus infection: Epidemiology and pathophysiologyGynecologic Oncology, 2007
- Down-regulation of MUC1 in cancer cells inhibits cell migration by promoting E-cadherin/catenin complex formationBiochemical and Biophysical Research Communications, 2007
- What Makes MUC1 a Tumor Antigen?Tumor Biology, 2005
- The MUC1 Oncoprotein Activates the Anti-apoptotic Phosphoinositide 3-Kinase/Akt and Bcl-xL Pathways in Rat 3Y1 FibroblastsJournal of Biological Chemistry, 2004
- Binding patterns of DTR-specific antibodies reveal a glycosylation-conditioned tumor-specific epitope of the epithelial mucin (MUC1)Glycobiology, 2004